Literature DB >> 17437521

Differences between endocrinologists and endocrine surgeons in management of the solitary thyroid nodule.

John P Walsh1, Simon A Ryan, Dean Lisewski, Mohammed Z Alhamoudi, Suzanne Brown, Finn N Bennedbaek, Lazlo Hegedüs.   

Abstract

BACKGROUND: It is not known whether management of the solitary thyroid nodule differs between endocrinologists and endocrine surgeons.
METHODS: A questionnaire containing a hypothetical case (a 42-year-old euthyroid woman with a 2-x-3-cm solitary thyroid nodule) and 13 clinical variations was sent to endocrinologists and endocrine surgeons in Australia.
RESULTS: The response rate was 51%, including 122 endocrinologists and 48 endocrine surgeons. For the index case, serum thyroid-stimulating hormone (TSH), fine needle aspiration biopsy (FNAB) and ultrasonography were widely used by both groups, but thyroid antibody tests and scintigraphy were ordered more commonly by endocrinologists. In the setting of benign cytology, treatment differed significantly between specialties for the index case (endocrinologists: no treatment 78%, surgery 11%, thyroxine 11%; surgeons: no treatment 73%, surgery 25%, thyroxine 2%; P = 0.032). Treatment recommendations also differed significantly for 12 of the 13 clinical variations. In particular, for a patient with a suppressed serum TSH concentration, a majority of endocrinologists recommended radioiodine treatment, whereas surgeons favoured surgery (endocrinologists: radioiodine 53%, surgery 22%, no treatment 25%; surgeons: surgery 60%, radioiodine 11%, no treatment 27%; P < 0.001). For most of the variations, a higher proportion of surgeons than endocrinologists recommended surgical treatment. Comparison with previous surveys of European Thyroid Association and American Thyroid Association members (predominantly endocrinologists) demonstrated considerable international differences in management.
CONCLUSION: There are clinically significant differences between Australian endocrinologists and endocrine surgeons in management of the solitary thyroid nodule, and international differences in management of this disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17437521     DOI: 10.1111/j.1365-2265.2007.02823.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  3 in total

1.  Down-sizing the overzealous search for low-risk thyroid malignancy.

Authors:  Laszlo Hegedüs
Journal:  Endocrine       Date:  2016-04-15       Impact factor: 3.633

2.  Thyroxine suppression therapy for benign, non-functioning solitary thyroid nodules: a quality-effects meta-analysis.

Authors:  Altayyeb Yousef; Justin Clark; Suhail A R Doi
Journal:  Clin Med Res       Date:  2010-08-25

Review 3.  Non-surgical approach to the benign nodular goiter: new opportunities by recombinant human TSH-stimulated 131I-therapy.

Authors:  Steen Joop Bonnema; Søren Fast; Laszlo Hegedüs
Journal:  Endocrine       Date:  2011-10-05       Impact factor: 3.633

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.